Adding Neurocognitive Component to Balance Test
Launched by DUKE UNIVERSITY · Feb 10, 2025
Trial Information
Current as of July 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The study team will measure performance under two conditions: the standard Y-Balance Test (YBT) and the YBT with an added neurocognitive component (YBT+NC). For the YBT+NC, the study team will attach Blaze Pods to the target area of the three reach indictors: anterior (A), posteromedial (PM), and posterolateral (PL). The Blaze Pods will light up in random sequences, requiring participants to slide the illuminated reach indicator as far as possible while maintaining balance on the stationary stance limb. Reaction time, individual reach distances (PM,PL,A), YBT composite score, and number of ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All participants: 18-25 years old
- • All participants: MARX activity questionnaire of greater than 10
- • All participants: able to follow verbal instructions
- • For patient participants: ACL Repair or Reconstruction within past 5-7 months
- Exclusion Criteria:
- • Healthy participants: Chronic Ankle Instability
- • Healthy participants: Prior lower extremity surgery
- • Healthy participants: LE injury \<6 months ago
- • Healthy participants: current LE pain
- • Healthy participants: visual deficits
- • Healthy participants: vestibular or neurological deficits affecting balance
- • Healthy participants: unable to maintain single leg stance for 10 seconds
- • Healthy participants: unable to read or speak English
- • For patient participants: Chronic Ankle Instability
- • For patient participants: current LE pain
- • For patient participants: multi-ligament procedure
- • For patient participants: prior surgery on uninvolved limb
- • For patient participants: visual deficits
- • For patient participants: vestibular or neurological deficits affecting balance
- • For patient participants: unable to read or speak English
- • For patient participants: unable to maintain single leg stance for 10 seconds
About Duke University
Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Durham, North Carolina, United States
Patients applied
Trial Officials
Robert Tisherman, MD
Principal Investigator
Duke University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported